Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.96 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)12.27M
Market Cap
$97.54B
Enterprise Value$131.71B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$50.93B
Price to Earnings (P/E)19.3
Beta0.26
Next Earnings
Oct 30, 2025EPS Estimate
1.69Last Dividend Ex-Date
Jul 03, 2025Dividend Yield5.22%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,035,435,800
10 Day Avg. Volume9,683,481
30 Day Avg. Volume12,272,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda8.73
Forecast
1Y Price Target
$50.79Price Target Upside7.74% Upside
Rating ConsensusHold
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGuidance for FY25 revenue was raised by $700 million, indicating strong future performance expectations.
Operational EfficiencyBristol is making solid progress with a $1 billion reduction in OPEX this year and clear reallocation in the pipeline.
Bears Say
Product LaunchesThe price target was lowered to $58 due to a slower Cobenfy launch and more uncertainty on future expansions.
Quality Of EarningsConcerns remain around the quality of the earnings beat, particularly the reliance on lower quality items such as legacy products, FX, and stocking.
Revenue ExpectationsCobenfy scripts are expected to miss Visible Alpha consensus estimates for 3Q25 revenue.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.96 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $97.54B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 30, 2025 which is in 65 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Aug 01, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.091 by $0.369.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 5.22%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.69.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.46 in its last earnings report, beating expectations of $1.091. Following the earnings report the stock price went up 2.124%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.79 (7.74% Upside)
$50.79 (7.74% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 89%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 350.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.36%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates in various therapeutic areas, including oncology, immunology, cardiovascular, and fibrosis, with a strong portfolio of pharmaceuticals and biologics. Core products include well-known drugs such as Opdivo, Eliquis, and Revlimid. BMY is committed to advancing science through research and collaborations to address unmet medical needs.
BMY Company Deck
BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.View all BMY earnings summariesBMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
BMY Stock 12 Month Forecast
Average Price Target
$50.79
▲(7.74% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
23.05% Mutual Funds
14.65% Other Institutional Investors
36.31% Public Companies and Individual Investors